Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b, Open-Label, Safety and Immunogenicity Study of SARS-CoV-2 mRNA-1273 Vaccine in Adult Solid Organ Transplant Recipients and Healthy Controls

NCT04860297 is registered in ClinicalTrials.gov with ModernaTX, Inc. as lead sponsor.

NCT NCT04860297
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04860297 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b, Open-Label, Safety and Immunogenicity Study of SARS-CoV-2 mRNA-1273 Vaccine in Adult Solid Organ Transplant Recipients and Healthy Controls
Lead sponsor
ModernaTX, Inc.
Phase
Phase 3
Overall status
Completed
Start date
April 16, 2021
Completion date
May 22, 2023
Enrollment
234 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov-2